NRx Pharmaceuticals

Update in progress

NRXP (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

NRx Pharmaceuticals, Inc. is a clinical‑stage biopharma company focused on CNS disorders in the United States, including suicidal depression, PTSD, and schizophrenia. It operates through NRx and Dura and develops NRX‑101 (oral D‑cycloserine with lurasidone) for bipolar depression with ideation, NRX‑100 (preservative‑free ketamine IV) for suicidal depression, and KETAFREE (generic ketamine). It also offers precision interventional psychiatry using neuroplastic drugs, TMS, digital therapeutics, hyperbaric therapy, ketamine infusion, and psychotherapy, under a Glytech LLC license. Founded 2015, Wilmington, Delaware.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.31; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive